APA (7th ed.) Citation

Mourey, L., Conter, H., Shore, N., Berry, W., Fong, P., Piulats, J., . . . Yu, E. (2020). 625P Pembrolizumab (pembro) plus enzalutamide (enza) in patients with abiraterone acetate (abi)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort C update. Annals of Oncology, 31, S516. https://doi.org/10.1016/j.annonc.2020.08.884

Chicago Style (17th ed.) Citation

Mourey, L., et al. "625P Pembrolizumab (pembro) Plus Enzalutamide (enza) in Patients with Abiraterone Acetate (abi)-pretreated Metastatic Castration-resistant Prostate Cancer (mCRPC): KEYNOTE-365 Cohort C Update." Annals of Oncology 31 (2020): S516. https://doi.org/10.1016/j.annonc.2020.08.884.

MLA (9th ed.) Citation

Mourey, L., et al. "625P Pembrolizumab (pembro) Plus Enzalutamide (enza) in Patients with Abiraterone Acetate (abi)-pretreated Metastatic Castration-resistant Prostate Cancer (mCRPC): KEYNOTE-365 Cohort C Update." Annals of Oncology, vol. 31, 2020, p. S516, https://doi.org/10.1016/j.annonc.2020.08.884.